Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2026-03-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company 华兰生物工程股份有限公司. It references regulatory notices from the Ministry of Finance of China and explains the nature and impact of the accounting policy changes. The document explicitly states that the changes do not require board or shareholder approval and do not materially affect financial results. The document is short (1290 characters) and serves as a formal disclosure of accounting policy changes rather than a full financial report or audit. It does not contain financial statements or detailed financial data. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2026-03-27 Chinese
第九届董事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the ninth board of directors' fourth meeting of 华兰生物工程股份有限公司. It includes approvals of various reports such as the 2025 annual general manager work report, board work report, annual report, profit distribution plan, internal control self-evaluation report, ESG report, and other governance and management related proposals. It also discusses board member resignations and appointments, amendments to company bylaws, and other corporate governance matters. The document repeatedly states that the detailed reports are published elsewhere (e.g., on 巨潮资讯网 and 证券时报) and that these resolutions will be submitted to the shareholders' meeting for approval. The document is not the annual report itself but an announcement of board meeting decisions including approval of the annual report and other related documents. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of board meeting resolutions and not the full annual report or other standalone reports.
2026-03-27 Chinese
审计委员会对年审会计师履职情况评估及对年审会计师履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the annual audit firm for the fiscal year 2025. It details the auditor's qualifications, audit procedures, communication with management, and the audit opinion issued. The document references the audit of the 2025 annual financial statements and internal controls, but it is not the annual report itself. It is a standalone audit-related report focusing on the auditor's performance and oversight, consistent with an Audit Report / Information filing. The document length is 2111 characters, which is relatively short but contains substantive audit evaluation content, not merely an announcement or certification. Therefore, it fits best under the Audit Report / Information (AR) category. FY 2025
2026-03-27 Chinese
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report on the use of funds by controlling shareholders and other related parties for the fiscal year ending December 31, 2025. It is issued by an accounting firm and references an audit report for the 2025 financial statements. The document includes detailed tables summarizing non-operating fund occupation and other related party fund transactions. It is a standalone audit-related report focusing on a specific regulatory requirement about related party fund usage, not a full annual report or general audit report. The document length is 3639 characters, which is relatively short but contains substantive financial data and audit-related commentary. This fits the category of an Audit Report / Information (AR) as it is a specialized audit-related disclosure rather than a full annual report or a simple announcement. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-03-27 Chinese
关于对参股公司华兰安康生物股份有限公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase (增资) in an associate company and related party transactions. It details the transaction, approval by the board and independent directors, and compliance with relevant laws and regulations. The document is relatively short (2787 characters) and focuses on a specific financing event involving related parties. It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, audit report, or earnings release. The content fits the category of a Capital/Financing Update, as it reports on a capital increase and related party transaction.
2026-03-27 Chinese
关于转让控股子公司股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of equity in a controlling subsidiary, which constitutes a related party transaction. It details the transaction terms, pricing, approvals by the board and committees, and the impact on the company. It is not a full financial report, earnings release, or management discussion, but rather a specific corporate announcement about a capital transaction involving related parties. The document is lengthy (6839 characters) and contains detailed transaction information, but it is not an annual or interim report, nor a merger filing. It fits best under Capital/Financing Update (CAP) as it concerns a significant equity transfer and related party transaction disclosures.
2026-03-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.